Balchem heads into its third-quarter report with its strongest top-line momentum in more than a year and a lingering question about how much of that growth is actually reaching the bottom line. Last quarter the company set records for revenue, adjusted EBITDA and adjusted earnings, powered by a sharp turn in Animal Nutrition & Health. Gross margin, however, barely budged, rising just 10 basis points to 36.5% as manufacturing input costs tied to the Middle East conflict ate into the benefit of higher volumes and better mix. The upcoming report should show whether that squeeze was a temporary speed bump or the start of a tougher cost environment.

The Street is looking for adjusted earnings of $1.53 a share on revenue of about $289.3 million, up 13.3% and 8.1%, respectively, from a year ago. Those are solid numbers, but they imply a step down from the 11.2% revenue growth and 17.3% earnings growth delivered last quarter. Sequentially, consensus asks for only about $5 million more in sales and four cents more in earnings than the second quarter's $1.49. Balchem does not issue formal revenue or EBITDA guidance, so there is no range to measure the Street against. Still, management's framing has clearly brightened, moving from talk of modest margin compression early in the year to confident commentary on growth and profitability last quarter. In that light, the estimates look more cautious than demanding.

The most important operating story remains Animal Nutrition & Health. Segment sales accelerated to 15% growth last quarter from under 9% in the first quarter and roughly 5% at the end of fiscal 2025, while operating earnings jumped nearly 49%. Management credited the European monogastric business, which has improved in both volume and price every quarter since EU anti-dumping duties took effect around the start of 2026, along with roughly 20% volume-driven growth in the higher-margin ruminant line. Confirmation would look like another quarter of mid-teens or better segment growth with profit growth still outpacing sales. A sharp fade would suggest the anti-dumping benefit was largely a one-time reset in pricing rather than a durable share recovery.

Margins are the second swing factor. Balchem's first-quarter gross margin expanded 210 basis points before the input-cost pressure arrived, so the trajectory of that metric will reveal whether pricing and mix can catch up with inflation. Flat or improving gross margin alongside continued sales leverage would validate the record-setting narrative and extend the company's streak of year-over-year EBITDA growth, now at 28 quarters. Another quarter of erosion, particularly in Human Nutrition & Health, where cost pressure partly offset margin gains, would challenge it. Smaller details matter too: free cash flow of $36 million last quarter trailed last year's pace, the tax rate drifted higher, and floating-rate borrowing leaves interest costs sensitive to Fed moves. Any update on the completed choline and Alzheimer's study, which management expected to publish within a couple of months, could add a longer-term talking point for the human nutrition franchise.

Sentiment remains heavily skewed to the bearish side, though slightly less so than ahead of the last report. The stock has gained 4.5% since then, modestly ahead of the S&P 500, and trades just above its 200-day moving average at about $170. That leaves shares in the middle of their post-earnings range, roughly 7% below the $182.99 high, so the market has nudged the stock higher without pricing in a blowout.

The central issue is whether Balchem can keep converting accelerating demand into accelerating profit. If Animal Nutrition & Health sustains its European recovery and gross margin holds its ground against input costs, the relatively modest consensus bar looks achievable. If margins slip again, the growth story stays intact but the earnings leverage that justified last quarter's enthusiasm comes into question.